CORT - Corcept Therapeutics Incorporated

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $125.33 DETAILS

Stock News

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined wit.

Sep 18, 2026 04:00 AM • businesswire.com

Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?

Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.

Sep 16, 2026 07:45 AM • zacks.com

Corcept Grows to Mid-Cap on Institutional Support

Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.

Sep 16, 2026 02:23 AM • fxempire.com

Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?

One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.

Sep 10, 2026 03:59 AM • fool.com

Corcept: Not Cheap, But Backed By Real Structural Growth

Corcept Therapeutics is evolving into a multi-engine growth platform, driven by expanding Cushing's and a rapid oncology ramp with Lifyorli. CORT delivered strong 2Q26 results: $256.1M revenue (+32% YoY), $47.6M Lifyorli launch, and maintained profitability despite elevated launch expenses. CATALYST and MOMENTUM studies reveal Cushing's is more prevalent than previously thought, structurally expanding the addressable market and supporting multi-billion-dollar revenue potential.

Sep 08, 2026 05:25 AM • seekingalpha.com

Bank of America Corp DE Grows Holdings in Corcept Therapeutics Incorporated $CORT

Bank of America Corp DE raised its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 33.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 111,736 shares of the biotechnology company's stock after acquiring an additional 28,078 shares during the period. Bank

Aug 29, 2026 12:03 AM • defenseworld.net

Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Aug 28, 2026 08:36 AM • zacks.com

Bank of New York Mellon Corp Invests $49.19 Million in Corcept Therapeutics Incorporated $CORT

Bank of New York Mellon Corp acquired a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 565,666 shares of the biotechnology company's stock, valued at approximately $49,185,000. Bank of New York Mellon Corp owned approximately

Aug 27, 2026 11:58 PM • defenseworld.net

BlackRock Inc. Makes New $1.08 Billion Investment in Corcept Therapeutics Incorporated $CORT

BlackRock Inc. bought a new stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,432,023 shares of the biotechnology company's stock, valued at approximately $1,080,964,000. BlackRock Inc. owned about 11.50% of

Aug 21, 2026 11:32 PM • defenseworld.net

Like The Knick's, Corcept Rebounded And Is Crushing It

Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.

Aug 20, 2026 11:18 PM • seekingalpha.com

Mega Cap Growth vs Small Cap Growth: Which ETF Wins?

MGK offers lower costs and mega-cap stability; SLYG delivered 27.4% returns over one year with broader diversification across industrials and healthcare.

Aug 18, 2026 12:30 PM • fool.com

Trump is up 230% on this stock trade since March

President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when the pharmaceutical company was trading at $35.69.

Aug 18, 2026 02:12 AM • finbold.com

Handelsbanken Fonder AB Boosts Stock Holdings in Corcept Therapeutics Incorporated $CORT

Handelsbanken Fonder AB grew its holdings in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 28.1% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 36,881 shares of the biotechnology company's stock after purchasing an additional 8,100 shares during the quarter. Handelsbanken Fonder

Aug 15, 2026 11:53 PM • defenseworld.net

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Aug 05, 2026 06:51 AM • zacks.com

Raised Guidance Lifts Corcept to 52-Week High

CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) as well as Cushing's syndrome.

Aug 05, 2026 02:47 AM • fxempire.com

FAS Wealth Partners Inc. Grows Stock Position in Corcept Therapeutics Incorporated $CORT

FAS Wealth Partners Inc. increased its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 4.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 322,370 shares of the biotechnology company's stock after buying an additional 12,352 shares during

Aug 03, 2026 01:23 AM • defenseworld.net

Avidity Partners Management LP Has $1.21 Million Position in Corcept Therapeutics Incorporated $CORT

Avidity Partners Management LP lifted its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 36.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,000 shares of the biotechnology company's stock after buying an additional 8,000 shares during the period.

Jul 31, 2026 11:49 PM • defenseworld.net

Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It

Corcept Therapeutics remains a 'Hold' as LIFYORLI's strong launch and clinical demand are already reflected in a premium valuation. LIFYORLI generated $47.6M in its first full quarter, with management targeting $1B+ US peak revenue and global NPV estimated at $4.24B. CORT's pipeline offers upside, notably with relacorilant in earlier PROC lines and EU approval pending, but non-LIFYORLI assets remain speculative.

Jul 31, 2026 07:34 AM • seekingalpha.com